pancreatic cancer with unresectable malignant obstruction of the distal biliary tract
Conditions
Interventions
12mm-diameter stent placement
10mm-diameter stent placement
Sponsors
Fujita Health University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Cases with jaundice or hepatic dysfunction. Jaundice has a serum total bilirubin level of 3.0 mg/dl or more, and liver dysfunction is blood transaminase, ALP, or GTP. (2) Patients with malignant histopathological confirmation. (3)Unresectable is confirmed by diagnostic imaging or patient background factors. (4)Expanded bile duct diameter is 12 mm or more by image diagnosis when confirming obstructive jaundice or liver function abnormality (5)Biliary stricture exists in the middle and lower parts that do not reach the hilum of the liver (6)Patients with ECOG Performance Status 0 or 1. (7)Expected survival time of 4 months or more (8)The age at the time of obtaining consent is 20 or more and less than 80.
Exclusion criteria
Exclusion criteria: (1) Reconstruction methods other than Billoth-I reconstruction are used after gastrectomy. (2) Patients with obstruction of the anus from the duodenal papilla. (3) Patients who had a metal stent in the past. (4) Cases with serious complications in other organs (ASA classification 3 or higher.) (5) Patients with acute pancreatitis and acute exacerbation of chronic pancreatitis. (6) Patients with cirrhosis (Child-Pugh Grade B or C) (7) Platelet count is 50,000/mm3 or less according to the latest test value within 28 days before registration. (8) In addition, patients who are judged by the attending physician to be inappropriate for conducting this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The patency of the 12mm-diameter metal stent. | — |
Countries
Japan
Contacts
Public ContactKazunori Nakaoka
Fujita Health University Department of Gastroenterology and Gastroenterological Oncology
Outcome results
None listed